- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
0.26
+0.01(+3.38%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.25
0.26
52 wk Range
0.21
0.78
CYAD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Celyad SA stock price live, this page displays EBR CYAD stock exchange data. View the CYAD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Celyad SA real time stock price chart below.
What Is the Celyad SA Stock Price Today?
The Celyad SA stock price today is 0.26.
What Is the Stock Symbol for Celyad SA?
The stock symbol for Celyad SA is "CYAD."
What Stock Exchange Does Celyad SA Trade On?
Celyad SA is listed and trades on the Brussels stock exchange.
Is Celyad SA a Good Stock to Buy?
Determining whether Celyad SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYAD quote. (ISIN: BE0974260896)
What Is the Celyad SA Stock Price Today?
The Celyad SA stock price today is 0.26.
What Is the Stock Symbol for Celyad SA?
The stock symbol for Celyad SA is "CYAD."
What Stock Exchange Does Celyad SA Trade On?
Celyad SA is listed and trades on the Brussels stock exchange.
Is Celyad SA a Good Stock to Buy?
Determining whether Celyad SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYAD quote. (ISIN: BE0974260896)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.250.26
52 wk Range
0.210.78
UnlockCYAD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Celyad Company Profile
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Compare CYAD to Peers and Sector
Metrics to compare | CYAD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYADPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −2.2x | −0.6x | |
PEG Ratio | −0.02 | −0.02 | 0.00 | |
Price/Book | 3.4x | 0.6x | 2.6x | |
Price / LTM Sales | 155.4x | 4.9x | 3.2x | |
Upside (Analyst Target) | - | 245.9% | 47.1% | |
Fair Value Upside | Unlock | 10.9% | 7.1% | Unlock |
FAQ
What Is the Celyad (CYAD) Stock Price Today?
The Celyad stock price today is 0.26.
What Stock Exchange Does Celyad Trade On?
Celyad is listed and trades on the Brussels stock exchange.
What Is the Stock Symbol for Celyad?
The stock symbol for Celyad is "CYAD."
What Is the Celyad Market Cap?
As of today, Celyad market cap is 10.77M.
What is Celyad Earnings Per Share?
The Celyad EPS is -0.221.
What Is the Next Celyad Earnings Date?
Celyad will release its next earnings report on 06 Nov 2024.
From a Technical Analysis Perspective, Is CYAD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.